UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2018-09, Vol.78 (18), p.5243-5258

2018

Volltextzugriff (PDF)

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

Clinical breast cancer, 2022-04, Vol.22 (3), p.269-278

2022

Volltextzugriff (PDF)

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Breast cancer research and treatment, 2017-08, Vol.164 (3), p.649-658

2017

Volltextzugriff (PDF)

Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy

Breast cancer research and treatment, 2016-11, Vol.160 (1), p.41-49

2016

Volltextzugriff (PDF)

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Clinical breast cancer, 2020-04, Vol.20 (2), p.89-97

2020

Volltextzugriff (PDF)

SIX PEOPLE TO KNOW

Educational horizons, 2012-10, Vol.91 (1), p.11-11

YOUNG, ROBYN R.

2012

Volltextzugriff (PDF)

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer

Cancer, 2010-05, Vol.116 (10), p.2301-2306

2010

Volltextzugriff (PDF)

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

Journal of cancer & allied specialties, 2016-05, Vol.2 (1)

2016

Volltextzugriff (PDF)

Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS11-29-PS11-29

2021

Volltextzugriff (PDF)

Use of a multiplexed immunoassay

Breast cancer research and treatment, 2016-11, Vol.160 (1), p.41

2016

Volltextzugriff (PDF)

Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e14565-e14565

2016

Volltextzugriff (PDF)

Abstract OT2-1-07: A phase II study with orteronel as monotherapy in patients with androgen receptor (AR) expressing metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.OT2-1-07-OT2-1-07

2015

Volltextzugriff (PDF)

Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy

Pharmacotherapy, 2000-11, Vol.20 (11), p.1318-1323

2000

Volltextzugriff (PDF)

Weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS1106-TPS1106

2015

Volltextzugriff (PDF)

METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS1110-TPS1110

2015

Volltextzugriff (PDF)

Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1068-1068

2013

Volltextzugriff (PDF)

Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS1137-TPS1137

2012

Volltextzugriff (PDF)

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2

Journal of clinical oncology, 2013-09, Vol.31 (26_suppl), p.155-155

2013

Volltextzugriff (PDF)

BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane

Journal of clinical oncology, 2012-09, Vol.30 (27_suppl), p.125-125

2012

Volltextzugriff (PDF)

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.553-553

2013

Volltextzugriff (PDF)

Eight Easy Steps to Maintain and Increase the Library Media Center Budget

Library media connection, 2008-01, Vol.26 (4), p.26

Young, Robyn R

2008

Volltextzugriff (PDF)

A spectrum of severe familial liver disorders associate with telomerase mutations

PloS one, 2009-11, Vol.4 (11), p.e7926-e7926

2009

Volltextzugriff (PDF)

Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration

Ophthalmology (Rochester, Minn.), 2015-06, Vol.122 (6), p.1212-1219

2015

Volltextzugriff (PDF)

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

Circulation (New York, N.Y.), 2015-11, Vol.132 (21), p.2037-2099

2015

Volltextzugriff (PDF)

Moving beyond panaceas in fisheries governance

Proceedings of the National Academy of Sciences - PNAS, 2018-09, Vol.115 (37), p.9065-9073

2018

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(137)
Mit Volltextzugriff
(134)

Publikationsform

Sprache

Englisch
(156)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer

A Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC)

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy

A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

SIX PEOPLE TO KNOW

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice‐daily regimen to treat patients with recurrent metastatic breast cancer

NEOADJUVANT WEEKLY NAB-PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY DOXORUBICIN PLUS CYCLOPHOSPHAMIDE WITH BEVACIZUMAB ADDED CONCURRENTLY TO CHEMOTHERAPY FOR OPERABLE TRIPLE-NEGATIVE INVASIVE BREAST CANCER

Abstract PS11-29: A phase 2 study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic triple-negative breast cancer (TNBC)

Use of a multiplexed immunoassay

Safety and immunologic activity of anakinra in HER2-negative metastatic breast cancer (MBC)

Abstract OT2-1-07: A phase II study with orteronel as monotherapy in patients with androgen receptor (AR) expressing metastatic breast cancer (MBC)

Randomized, Multicenter Comparison of Oral Granisetron and Oral Ondansetron for Emetogenic Chemotherapy

Weekly nab -paclitaxel ( nab -P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity)

METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC)

Pathologic complete response (pCR) with weekly nanoparticle albumin bound (nab-P) plus carboplatin (C) followed by doxorubicin plus cyclophosphamide (AC) with concurrent bevacizumab (B) for triple-negative breast cancer (TNBC)

Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2

BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane

Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2

Eight Easy Steps to Maintain and Increase the Library Media Center Budget

A spectrum of severe familial liver disorders associate with telomerase mutations

Two-Year Outcomes of “Treat and Extend” Intravitreal Therapy for Neovascular Age-Related Macular Degeneration

Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society

Moving beyond panaceas in fisheries governance

Suchergebnisse filtern